Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Bladder Carcinoma × pembrolizumab × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 116 Carcinoma, Transitional Cell 76 Carcinoma, Non-Small-Cell Lung 73 Urinary Bladder Neoplasms 71 Melanoma 65 Prostatic Neoplasms 45 Squamous Cell Carcinoma of Head and Neck 44 Colorectal Neoplasms 40 Stomach Neoplasms 32 Ovarian Neoplasms 32 Triple Negative Breast Neoplasms 29 Uterine Cervical Neoplasms 28 Neoplasm Metastasis 28 Kidney Neoplasms 26 Parkinson Disease 4, Autosomal Dominant Lewy Body 25 Breast Neoplasms 25 Neoplasms 24 Lung Neoplasms 23 Pancreatic Neoplasms 21 Carcinoma, Hepatocellular 21 Esophageal Neoplasms 20 Head and Neck Neoplasms 19 Endometrial Neoplasms 17 Small Cell Lung Carcinoma 14 Carcinoma, Merkel Cell 10 Mesothelioma 9 Cholangiocarcinoma 8 Carcinoma, Ovarian Epithelial 8 Sarcoma 7 Carcinoma 7

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02736266 2023-07-18

PURE-01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡